Update on Brazilian biosimilar enoxaparins.
Brazil is among the first countries approving the commercialization and clinical use of biosimilar enoxaparins. Our research group has performed quality control assessments of these drugs over the last decade. Areas covered: We have not found noticeable differences between Brazilian biosimilar enoxaparins and the original product regarding their physicochemical properties, disaccharide composition, anticoagulant activity, bioavailability and safety. Expert commentary: In spite of clinical and pharmacological advantages of enoxaparin, subcutaneous formulations of unfractionated heparin are employed by the Brazilian public health system for prevention and treatment of thromboembolism. The underuse of both original and biosimilar enoxaparins in Brazil directly correlates with their high cost.
a Hospital Universitário Clementino Fraga Filho and Instituto de Bioquímica Médica Leopoldo de Meis , Universidade Federal do Rio de Janeiro (UFRJ) , Rio de Janeiro , Brazil.
Eduardo
E
Vilanova
a Hospital Universitário Clementino Fraga Filho and Instituto de Bioquímica Médica Leopoldo de Meis , Universidade Federal do Rio de Janeiro (UFRJ) , Rio de Janeiro , Brazil.
Bianca F
BF
Glauser
a Hospital Universitário Clementino Fraga Filho and Instituto de Bioquímica Médica Leopoldo de Meis , Universidade Federal do Rio de Janeiro (UFRJ) , Rio de Janeiro , Brazil.
Stephan-Nicollas M C G
SM
Oliveira
a Hospital Universitário Clementino Fraga Filho and Instituto de Bioquímica Médica Leopoldo de Meis , Universidade Federal do Rio de Janeiro (UFRJ) , Rio de Janeiro , Brazil.
Ana M F
AM
Tovar
a Hospital Universitário Clementino Fraga Filho and Instituto de Bioquímica Médica Leopoldo de Meis , Universidade Federal do Rio de Janeiro (UFRJ) , Rio de Janeiro , Brazil.
Paulo A S
PA
Mourão
D000925:Anticoagulants / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals; D001938:Brazil; D003362:Cost-Benefit Analysis; D017984:Enoxaparin / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D013923:Thromboembolism / Q000188:drug therapy*
D000925:Anticoagulants; D059451:Biosimilar Pharmaceuticals; D017984:Enoxaparin
Low-molecular-weight heparin; anticoagulant drugs; antithrombotic agents; biological drugs; generic drugs; heparin